VPVít Procházka

Vít Procházka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vít Procházka has a total of 453 co-authors. Here are the top co-authors by number of shared publications:

  • Ludek Raida

    Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    14 shared publications
  • Tomas Papajik

    A Department of Hemato-Oncology, Faculty of Medicine and Dentistry , Palacky University and University Hospital , Olomouc , Czech Republic

    14 shared publications
  • Marek Trneny

    First Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic

    13 shared publications
  • Karel Indrak

    Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic

    12 shared publications
  • Tomáš Papajík

    Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic

    11 shared publications
  • Tomáš Papajík

    Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic

    11 shared publications

Latest Publications

  • Survival improvement of patients with DLBCL treated with third-line and beyond in the recent era in the Czech Republic

    by Prokop Vodička, Andrea Janíková, Kamila Polgárová, Juraj Ďuraš, Alice Sýkorová, František Folber, KateřIna Steinerová, Heidi Móciková, Vít Procházka, KateřIna Benešová, et al.

    The prognosis of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) has been considered to be poor. Although innovative agents such as CAR-T, bispecific antibodies, and antibody-drug conjugates have transformed the therapeutic landscape, their impact on survival at population level has not been comprehensively evaluated. We therefore aimed to assess temporal changes in overall survival (OS) among patients receiving third-line (L3) therapy in recent years. We analyzed 312 consecutive L3-treated r/r DLBCL patients from the prospective NiHiL project (NCT03199066) of the Czech Lymphoma Study Group. Patients were divided in two treatment eras based on CAR-T availability: Era 1 (2018-2020; n=134) and Era 2 (2021-2023; n=178). The primary endpoint was OS; secondary endpoints were event-free survival (EFS), response rates, and treatment patterns. OS significantly improved in Era 2 compared with Era 1 (HR=0.70, P=0.01), with 2-year OS of 43% versus 29%, respectively. Two-year EFS increased from 13% to 24% (HR=0.70; P=0.01). Complete remission rates improved from 18% to 30% (P=0.02). Treatment patterns shifted markedly, with increased use of CAR-T therapy (6% to 32%) and other novel agents (13% to 22%; P<0.01). More pronounced survival benefit was observed in CAR-T-eligible cohort (n=202). This real-world study is the first to demonstrate that the incorporation of new therapies has led to significant and clinically meaningful OS improvement in the general r/r DLBCL L3-treated population. These findings underscore the importance of continued integration and sequencing of innovative treatments into clinical practice and inclusion of patients in clinical trials.

  • Open Access

    Comorbidity Burden and Prognosis in Patients Aged 80+ Years With Large B-Cell Lymphoma

    by Prokop Vodička, Michal Masár, Carrie A. Thompson, David Belada, George A. Cholack, KateřIna Benešová, Izidore S. Lossos, Heidi Móciková, Diana Maláriková, AnnaLynn M. Williams, et al.

  • Open Access

    Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma

    by Sanjal H. Desai, Susan M. Geyer, Levi Pederson, Michael A. Spinner, Veronika Bachanova, Andrew M. Evens, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacques Azzi, et al.

    Patients with classic Hodgkin lymphoma (cHL) with primary refractory disease, early relapse, or extranodal disease have a higher risk of relapse after salvage therapy and autologous stem cell transplant (ASCT). Post-ASCT brentuximab vedotin (BV) maintenance improved progression-free survival (PFS) in high-risk relapsed/refractory (R/R) cHL in the AETHERA trial, but subgroup analysis suggested that the benefit in patients transplanted in complete metabolic response (CMR) is unclear. In a large international real-world cohort, we assessed the efficacy of BV maintenance stratified by pre-ASCT metabolic response and by the number of clinical risk factors as defined in the AETHERA trial. Adult patients with R/R cHL who met AETHERA risk criteria were included. Utilizing propensity score analyses, PFS and OS were assessed overall and in subgroups of CMR (442 pts) and partial metabolic response (PMR, 249 pts). We observed that post-ASCT BV maintenance was associated with significantly higher PFS in the subgroup with PMR (5-year PFS: 59.6% vs 43.3% HR = 0.52, CI95: 0.33-0.82; p = 0.007). In the subgroup of patients with CMR, BV maintenance did not significantly improve PFS (5-year PFS: 75.8% vs 62.3% HR = 0.88, CI95: 0.59-1.32; p = 0.29). However, when focusing on patients with CMR treated post-FDA approval of BV, there was a significant PFS benefit observed in those treated with BV maintenance vs. not (5-year PFS: 81.2% vs 55.2% HR = 0.40, CI95: 0.22-0.72; p = 0.003). Overall, BV maintenance after ASCT remains an important therapy for high-risk R/R cHL patients, especially for those in PMR or those in CMR.

  • Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy

    by Prokop Vodička, Tarec Christoffer El-Galaly, Vít Procházka, Christopher R. Flowers, Diego Villa, Caroline E. Dietrich, Lasse H. Jakobsen, Hervé Ghesquières, Michael R. Clausen, Robert Kridel, et al.

    A short diagnosis-to-treatment interval independently predicts inferior outcomes in follicular lymphoma. Using international discovery and validation cohorts, we demonstrate its prognostic value beyond established prognostic indices, with implications for risk stratification, clinical trial design, and interpretation.

  • Open Access

    Soluble cytokines enhance risk prediction across all stages of classical Hodgkin lymphoma

    by Alexandra Kredátusová, Tomáš Chupáň, Heidi Móciková, Alice Sýkorová, Jana Marková, Marie Lukášová, Ľubica Gahérová, Pavla Štěpánková, Eva Kriegová, Mária Maco, et al.

    Classical Hodgkin lymphoma (cHL) is a heterogeneous malignancy with favorable outcomes, but accurate prognostic stratification remains challenging, particularly across all disease stages. Traditional risk models are focused on advanced stages and do not account for tumor microenvironment (TME) dynamics. Soluble cytokines reflecting TME activity may offer additional prognostic value. In our prospective multicenter study, we investigated the prognostic value of pretreatment plasma levels of soluble TARC, sCD30, sCD163, and sIL-6 in 162 newly diagnosed cHL patients and developed a model incorporating these biomarkers for risk prediction across all stages. Cytokine levels were measured using ELISA, and clinical characteristics, treatment responses, and outcomes were collected. The primary endpoint was 5-year progression-free survival (PFS). Elevated levels of sIL-6 and sCD30 were associated with higher disease stage, presence of B-symptoms, extranodal involvement, and inferior 5-year PFS. A novel prognostic model incorporating age, extranodal disease, and high sCD30/sIL-6 levels outperformed IPS-3 in predicting therapy failure. Patients with both elevated sCD30 and sIL-6 levels at diagnosis had significantly worse outcomes. Integrating soluble cytokine biomarkers, particularly sIL-6 and sCD30, into prognostic models enhances risk stratification across all stages of cHL and supports future efforts toward biomarker-driven, personalized treatment strategies.


  • Top Cited Papers

    FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

    by Matthew J. Maurer, Vit K. Prochazka, Tarec Christoffer El-Galaly, Christopher R. Flowers, Diego Villa, Emmanuel Bachy, Elliot J. Cahn, Marguerite Fournier, Melissa C. Larson, Caroline E. Dietrich, et al.

    PURPOSE: Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS: The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074). RESULTS: The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL. CONCLUSION: The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.


  • Open Access

    The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab

    by Veronika Hanáčková, Jan Grohmann, Helena Urbánková, Hana Študentová, Eva Buriánková, Lenka Henzlová, Tomáš Papajík, Veronika Bachanová, Vít Procházka

    The simultaneous occurrence of Hodgkin lymphoma (HL) and ovarian carcinoma (OC) is rare and presents unique challenges in diagnosis and treatment. Circulating tumour DNA (ctDNA) offers a minimally invasive method for detecting minimal residual disease in both malignancies. We present the case of a 42-year-old woman with relapsed HL and advanced high-grade serous OC, treated with nivolumab, a PD-L1 inhibitor. After surgery and chemotherapy for OC, she received salvage therapy for cHL, including autologous stem cell transplantation. During the therapy, the patient was monitored using PET/CT and ctDNA analysis. CtDNA analysis detected a Hodgkin-driven compound mutation in the STAT6 gene (N417Y/N421S) allowing early relapse detection and treatment adjustments, detected progression of the disease led to nivolumab initiation. The mutation was used to monitor minimal residual disease (MRD). For ovarian carcinoma, presence of the BRAF V600E mutation as the marker was detected from archival paraffin-embedded ovarian tissue collected at the time of diagnosis, during ctDNA monitoring, BRAF V600E associated with OC remained undetectable, aligning with remission. This case highlights the potential of ctDNA to improve monitoring of concurrent malignancies, especially during immunotherapy, where PET/CT may lead to false-positive results. It is the first reported case of nivolumab treatment for chemo-refractory relapsed HL and OC, demonstrating the utility of ctDNA in managing dual malignancies.

  • Open Access

    Enhancing prognostic accuracy in PMBCL: semiquantitative analysis of interim PET/CT scans

    by V. Hanáčková, K. Polgárová, L. Henzlová, D. Zogala, A. Obr, M. Trněný, T. Papajík, V. Procházka

    Primary mediastinal large B-cell lymphoma (PMBCL) is a rare, aggressive lymphoma affecting young adults. Interim PET/CT (iPET/CT) scans are used to assess treatment response, but the positive predictive value of standard Deauville score remains limited. This retrospective multicenter study analyzed 116 PMBCL patients treated with anthracycline-based chemoimmunotherapy, focusing on 90 patients with high quality iPET/CT. Semiquantitative radiomics metrics, including changes in maximum standardized uptake value (dSUVmax), metabolic tumor volume (dMTV), and total lesion glycolysis (dTLG), were assessed alongside event-free survival (EFS). All interim and final PET/CT scans were independently reviewed by two nuclear medicine physicians blinded to outcomes. Among the 90 patients, 62 (68.9%) were iPET-positive (Deauville scores 4–5). Event-free survival (EFS) at 3 years was significantly higher in iPET-negative patients compared to iPET-positive patients (75% vs. 29%; p < 0.01). Radiomics analysis demonstrated that dSUVmax, dMTV, and dTLG provided superior predictive accuracy for EFS. Values below optimized cut-off thresholds demonstrated significantly better outcomes (e.g., 3-y EFS: 77.8% for dSUVmax ≥ 80% vs. 11.1% for dSUVmax < 80%, p < 0.01). Radiomics-based metrics outperformed visual iPET/CT assessment in identifying high-risk patients, underscoring their potential in guiding treatment. Future research should integrate radiomics with clinical factors to enhance PET-guided treatment strategies.

  • Open Access

    Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

    by Ajay Subramanian, Shengqin Su, Jamie Flerlage, Stefan Alig, Sheren Younes, Lianna J. Marks, Chelsea Pinnix, Francisco Vega, Raphael Steiner, Priya Kumar, et al.

    Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and few studies have comprehensively investigated the immune microenvironment and rare lymphocyte-predominant (LP) cells. Here we develop a NLPHL specific lymphocyte-predominant ecotype (LPE) model to identify 34 distinct cell states across 14 cell types that co-occur within 3 LPEs for 171 cases. LPE1 and LPE2 were characterized by immunosuppressive microenvironments with high expression of B2M on LP cells, CD8 T-cell exhaustion, immune checkpoint genes expressed by follicular T-cells, and an improved freedom from progression compared to LPE3 in training (n = 109, with 65% LPE1/2) and validation cohorts (n = 62, with 61% LPE1/2). We validate the co-occurrence and co-localization of cell states using spatial transcriptomics. Protein expression of HLA-I and HLA-II on LP cells and SSTR2 on dendritic cells was predictive of LPE1 (C-statistic=0.69), LPE2 (C-statistic=0.79), and LPE3 (C-statistic=0.60). This study establishes a clinically relevant biologic categorization for NLPHL.


  • Open Access

    Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety

    by Kateřina Dědečková, Michal Andrlik, Heidi Móciková, Lucia Kaliská, Simona Zapletalová, Jiří Kubeš, Sarah Al-Hamami, David J. Cutter, Georgios Ntentas, Vladimír Vondráček, et al.